VETERINARY
DIAGNOSTICS
866.647.2847

MiraVista Institutional Biosafety Committee (IBC) Announcement

Mar 3, 2021 | News

In compliance with NIAID/NIH guidelines research at MiraVista Diagnostics utilizing synthetic or recombinant DNA is annually reviewed by the MiraVista Institutional Biosafety Committee (IBC). The IBC is made up of internal and external subject matter experts to ensure...

Andrew Hanzlicek, DVM, MS, DACVIM (SAIM), Clinician Director

Feb 9, 2021 | Bios

Meet Andrew Hanzlicek, DVM, MS, DACVIM (SAIM), Clinician Director Andrew Hanzlicek, DVM, MS, DACVIM (SAIM), is a veterinary internal medicine specialist with more than 14 years of professional experience teaching, providing clinical services and conducting research in...

Test Report Updates for 2021

Nov 30, 2020 | News

In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our referral testing customers. Beginning March 1, 2021 MiraVista Diagnostics will transition to an improved MVista® Histoplasma Antigen Quantitative...

Are You Underdiagnosing Coccidioidomycosis?

May 14, 2020 | News

Are You Underdiagnosing Coccidioidomycosis? Capture Additional Cases with Combined Antigen and Antibody Testing. Dear Colleagues, The prevailing method for diagnosis of coccidioidomycosis is serum antibody testing by immunodiffusion (ID) with a sensitivity of 84.2%...

Test Report Updates for 2020

May 6, 2020 | News

In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our test report format to our referral testing customers. Minor changes have been made to the layout, while critical information such as test code,...

Only Available at MiraVista Diagnostics: MycoMEIA® Aspergillus Galf Urine EIA
MiraVista Diagnostics now offers MycoMEIA® Aspergillus Galf Urine EIA, a urine-based antigen assay that complements serum galactomannan (GM) testing and may improve diagnostic confidence for invasive aspergillosis (IA).

Learn More
X